Cargando…
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies
BACKGROUND: CD20 is a B cell lineage–specific marker expressed by normal and leukemic B cells and targeted by several antibody immunotherapies. We have previously shown that the protein from a CD20 mRNA splice variant (D393-CD20) is expressed at various levels in leukemic B cells or lymphoma B cells...
Autores principales: | Gamonet, Clémentine, Bole-Richard, Elodie, Delherme, Aurélia, Aubin, François, Toussirot, Eric, Garnache-Ottou, Francine, Godet, Yann, Ysebaert, Loïc, Tournilhac, Olivier, Caroline, Dartigeas, Larosa, Fabrice, Deconinck, Eric, Saas, Philippe, Borg, Christophe, Deschamps, Marina, Ferrand, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774009/ https://www.ncbi.nlm.nih.gov/pubmed/26937306 http://dx.doi.org/10.1186/s40164-016-0036-3 |
Ejemplares similares
-
Erratum to: New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies
por: Gamonet, Clémentine, et al.
Publicado: (2016) -
Lymphoblastic T Cells and Mature NK Cells With the Same TCRγ Rearrangement: A Common Origin?
por: Roggy, Anne, et al.
Publicado: (2021) -
Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm
por: Philippe, Laure, et al.
Publicado: (2017) -
Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells
por: Caël, Blandine, et al.
Publicado: (2022) -
BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
por: Poussard, Margaux, et al.
Publicado: (2020)